Infliximab · intravenous infusion
Misc., Injections & Implants
OFF-LABELNot in the FDA label for this product
Refractory non-infectious uveitis
Intravenous infusion at weeks 0, 2 and 6, then every 8 weeks, with dose escalation permitted for breakthrough inflammation in the trial
Open-label · n=23 · toxicity
A prospective open-label phase 2 trial enrolled 23 patients with refractory autoimmune uveitis. 18 of 23 (78%) met a composite success endpoint at week 10, and all patients who completed 50 weeks maintained it. The safety signal is the reason to read this row carefully rather than the efficacy: 5 of the 14 enrolled for a year stopped early for significant adverse events, serious events potentially related to infliximab included pulmonary embolus, congestive heart failure, lupus-like reaction in 2 patients and vitreous hemorrhage in 2, and antinuclear antibodies developed in 15 of 20 patients receiving 3 or more infusions. The authors call the rate of serious toxic effects unexpectedly high.
Contraindications
- Doses above 5 mg/kg in moderate or severe heart failure
- Previous severe hypersensitivity reaction to infliximab, any inactive ingredient of REMICADE or any murine protein
100 mg single-dose vial
Infliximab neutralizes the biological activity of TNFα by binding with high affinity to the soluble and transmembrane forms of TNFα and inhibits binding of TNFα with its receptors. Infliximab does not neutralize TNFβ (lymphotoxin-α), a related cytokine that utilizes the same receptors as TNFα.
Warnings & Precautions
- Serious infections: REMICADE raises the risk of serious infections that may lead to hospitalization or death, including active tuberculosis, invasive fungal infections and other opportunistic infections. This carries a boxed warning. Test for latent tuberculosis before and during therapy, and start treatment for latent infection before REMICADE. Do not give REMICADE during an active infection. Monitor closely for infection during and after treatment, and stop REMICADE if a serious infection or sepsis develops.
- Invasive fungal infections: for patients who reside or travel in regions where mycoses are endemic, invasive fungal infection should be suspected if they develop a serious systemic illness. Appropriate empiric antifungal therapy should be considered while a diagnostic workup is being performed. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection.
- Malignancies: lymphoma and other malignancies, some fatal, have been reported in children and adolescents treated with TNF blockers, including REMICADE. The incidence of malignancies, including invasive cervical cancer and lymphoma, was greater in REMICADE-treated patients than in controls. Malignancy is part of the boxed warning. Use caution when considering REMICADE in patients with a history of malignancy or with moderate to severe COPD, and when continuing it in patients who develop malignancy.
- Leukemia: cases of acute and chronic leukemia have been reported with postmarketing TNF blocker use in RA and other diseases.
- Skin cancer: melanoma and Merkel cell carcinoma have been reported with TNF blocker therapy, including REMICADE. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer, and Ps patients should be monitored for nonmelanoma skin cancers, particularly after prior prolonged phototherapy.
- Cervical cancer: a registry study found a 2 to 3 fold increase in the incidence of invasive cervical cancer in women with RA treated with REMICADE compared to biologics-naïve patients or the general population, particularly those over 60 years of age. A causal relationship between REMICADE and cervical cancer cannot be excluded. Periodic screening should continue in women treated with REMICADE.
- Hepatosplenic T-cell lymphoma: postmarketing cases of this rare T-cell lymphoma, with a very aggressive course and fatal outcome, have been reported with TNF blockers, including REMICADE, and the boxed warning names it. Almost all patients had also received azathioprine or 6-mercaptopurine. Most REMICADE cases occurred in CD or UC, and most were in adolescent or young adult males. Carefully assess the risk/benefit, especially in males with these diseases on azathioprine or 6-mercaptopurine.
- Hepatitis B virus reactivation: TNF blockers, including REMICADE, have been associated with HBV reactivation in chronic carriers, and in some instances it has been fatal. Test for HBV infection before starting REMICADE, and consult a hepatitis B expert if hepatitis B surface antigen is positive. Monitor carriers closely during therapy and for several months after it ends. If HBV reactivates, stop REMICADE, start antiviral therapy with appropriate supportive treatment, and use caution about resuming it.
- Hepatotoxicity: severe hepatic reactions, including acute liver failure, jaundice, hepatitis and cholestasis, have been reported, some fatal or needing liver transplantation. Evaluate patients with symptoms or signs of liver dysfunction for evidence of liver injury. Stop REMICADE in cases of jaundice and/or marked liver enzyme elevations (e.g., ≥5 times the upper limit of normal).
- Heart failure: REMICADE at doses above 5 mg/kg is contraindicated in moderate or severe heart failure, and new onset and worsening heart failure have been reported after marketing. Monitor closely any patient with heart failure who receives it, and stop REMICADE if new or worsening symptoms appear.
- Cardiovascular, cerebrovascular and visual reactions: transient visual loss has been reported during or within 2 hours of a REMICADE infusion. Serious cerebrovascular accidents, myocardial ischemia or infarction (some fatal), hypotension, hypertension and arrhythmias have been reported during and within 24 hours of starting an infusion. Monitor patients during infusion, and stop it if a serious reaction occurs.
- Cytopenias: leukopenia, neutropenia, thrombocytopenia and pancytopenia, some fatal, have been reported, although the causal relationship to REMICADE remains unclear. Use caution in patients with ongoing or past significant hematologic abnormalities. Advise all patients to seek immediate medical attention if signs and symptoms suggestive of blood dyscrasias or infection, such as persistent fever, develop, and consider stopping REMICADE in patients who develop significant hematologic abnormalities.
- Hypersensitivity: serious infusion reactions including anaphylaxis or serum sickness-like reactions may occur. Most hypersensitivity reactions have occurred during or within 2 hours of infusion. Keep treatment medications available and discontinue REMICADE for severe hypersensitivity reactions.
- Serum sickness-like reactions: in some cases these have been observed after initial REMICADE therapy (as early as after the second dose), and when REMICADE was reinstituted after an extended period without it. In RA, CD and Ps trials, re-administration after a period of no treatment resulted in a higher incidence of infusion reactions than regular maintenance treatment.
- Neurologic reactions: REMICADE and other agents that inhibit TNF have been associated with CNS manifestations of systemic vasculitis, seizure, and new or worsening central nervous system demyelinating disorders, including multiple sclerosis and optic neuritis, and peripheral demyelinating disorders, including Guillain-Barré syndrome; use caution in patients with these disorders and consider stopping REMICADE if they develop.
- Serious infections and neutropenia: these were seen with concurrent anakinra and etanercept, another TNF blocker, with no added clinical benefit, and TNF blockers with abatacept have been associated with more infections, including serious infections. Concurrent use of REMICADE with anakinra, abatacept or other biological products for the same conditions is not recommended. Take care when switching biologics, since overlapping biological activity may further increase the risk of infection.
- Lupus-like syndrome: REMICADE may cause autoantibodies and a lupus-like syndrome; stop treatment if symptoms suggest one.
- Disseminated infections: live vaccines and therapeutic infectious agents may result in clinical infections and should not be given with REMICADE. Update vaccinations before starting it. A fatal disseminated BCG infection was reported in an infant vaccinated after in utero exposure to infliximab, which crosses the placenta and has been detected up to 6 months after birth. At least a six month waiting period after birth is recommended before any live vaccine in an infant exposed in utero.
Common Side Effects
The most common adverse reactions (>10%) are infections (e.g. upper respiratory, sinusitis, and pharyngitis), infusion-related reactions, headache, and abdominal pain. In RA patients who received 4 or more infusions, upper respiratory tract infection occurred in 32% of REMICADE patients versus 25% on placebo, nausea in 21%, headache in 18%, sinusitis in 14%, and diarrhea, abdominal pain, pharyngitis and coughing in 12% each. Approximately 20% of REMICADE-treated patients had an infusion reaction, compared with 10% of placebo-treated patients. Abdominal pain occurred in 26% of REMICADE-treated patients with CD.
Pregnancy: Available observational studies in pregnant women exposed to REMICADE showed no increased risk of major malformations among live births as compared to those exposed to non-biologics. However, findings on other birth and maternal outcomes were not consistent across studies of different study design and conduct. Monoclonal antibodies such as infliximab are transferred across the placenta during the third trimester of pregnancy and may affect immune response in the in utero exposed infant. Infliximab has been detected in the serum of infants up to 6 months following birth, and these infants may be at increased risk of infection, including disseminated infection which can become fatal.
Lactation: Published literature show that infliximab is present at low levels in human milk. Systemic exposure in a breastfed infant is expected to be low because infliximab is largely degraded in the gastrointestinal tract.
The safety and effectiveness of REMICADE have been established in pediatric patients 6 to 17 years of age for induction and maintenance treatment of CD and UC. Safety and effectiveness have not been established in pediatric patients <6 years of age with CD or UC, or in pediatric patients with Ps or juvenile rheumatoid arthritis (JRA). Due to the risk of HSTCL, a careful risk-benefit assessment should be made when REMICADE is used in combination with other immunosuppressants in pediatric CD and UC patients.